Role of CD10 Marker in Differentiating Malignant Thyroid Neoplasms from Benign Thyroid Lesions (Immunohistochemical & Histopathological Study)

Samia Mohamed Gabal; Mostafa Mohamed Salem; Rasha Ramadan Mostafa; Shaimaa Mohamed Abdelsalam

doi:10.3889/oamjms.2018.456

Authors

Samia Mohamed Gabal Cairo University, Cairo, Egypt
Mostafa Mohamed Salem Cairo University, Cairo, Egypt
Rasha Ramadan Mostafa Cairo University, Cairo, Egypt
Shaimaa Mohamed Abdelsalam Cairo University, Cairo, Egypt

DOI:

https://doi.org/10.3889/oamjms.2018.456

Keywords:

malignant thyroid neoplasms, benign thyroid lesions, CD10, Immunohistochemical.

Abstract

BACKGROUND: CD10 was initially recognised as a cellâ€“surface antigen expressed by acute lymphoblastic leukaemias, and hence itâ€™s early designation as Common Acute Lymphoblastic Leukemia Antigen (CALLA). Also, it has been proven to be reactive in various non-lymphoid cells and tissue and different types of neoplasms.

AIM: To evaluate the immunohistochemical expression of CD10 in malignant thyroid neoplasms and different benign lesions and to assess whether CD10 can be used as a malignancy marker in thyroid pathology or not.

MATERIAL AND METHODS: A total of 83 archived, formalin fixed, paraffin embedded tissue blocks of 83 cases of malignant thyroid neoplasms and different benign lesions. The samples were immunohistochemically analysed for CD10 expression. A p-value of less than 0.05 was considered statistically significant.

RESULTS: CD10 was expressed in 91% of the studied malignant thyroid neoplasms and 58% of benign thyroid lesions. It was expressed in 26 of 28 (92.9%) conventional papillary carcinomas, ten of 10 (100%) follicular variants of papillary carcinoma, seven of nine (77.8%) minimally invasive follicular carcinomas, two of three (66.7%) widely invasive follicular carcinomas, and seven of 7 (100%) undifferentiated carcinomas, seven of 11 (66.7%) adenomatous nodules and eight of 15 (53.3%) follicular adenomas. No statistically significant correlations were detected between CD10 expression and patientsâ€™ age, sex, lymph node metastasis, tumour stage and capsular invasion.

CONCLUSION: CD10 shows strong sensitivity (91.2%) and moderate specificity (42.3%) in the diagnosis of malignancy overall and shows strong sensitivity (86.4%) and moderate specificity (42.3%) in the diagnosis of malignancy in the follicular-patterned lesions. So, CD10 might be useful in differentiating malignant from benign thyroid lesions (good positive test) and in the diagnosis of follicular variant of papillary carcinoma.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Nikiforov YE, Biddinger PW, Thompson LD, editors. Diagnostic pathology and molecular genetics of the thyroid: a comprehensive guide for practising thyroid pathology. Lippincott Williams & Wilkins, 2012.

Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK, HÃ¶lzer S, US and German Thyroid Cancer Study Group. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996: an American college of surgeons commission on cancer patient care evaluation study. Cancer. 2000; 89(1):202-17. https://doi.org/10.1002/1097-0142(20000701)89:1<202::AID-CNCR27>3.0.CO;2-A

Minamimoto R, Senda M, Jinnouchi S, Yoshida T, Nakashima R, Nishizawa S, Terauchi T, Kawamoto M, Inoue T. Assessment of diagnostic criteria for FDG-PET cancer screening program according to the interpretation of FDG-PET and combined examination. Kaku igaku. The Japanese journal of nuclear medicine. 2009; 46(2):73-93.

Duggal R, Rajwanshi A, Gupta N, Vasishta RK. Interobserver variability amongst cytopathologists and histopathologists in the diagnosis of neoplastic follicular patterned lesions of the thyroid. Diagnostic cytopathology. 2011; 39(4):235-41. https://doi.org/10.1002/dc.21363 PMid:21416635

Beesley MF, McLaren KM. Cytokeratin 19 and galectinâ€3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology. 2002; 41(3):236-43. https://doi.org/10.1046/j.1365-2559.2002.01442.x

Williams ED, Chernobyl Pathologists Group (A. Abrosimov, T. Bogdanova, M. Ito, J. Rosai, Yu Sidorov, GA Thomas). Guest editorial: two proposals regarding the terminology of thyroid tumours. 2000:181-183.

Evans HL. Follicular neoplasms of the thyroid. A study of 44 cases followed for a minimum of 10 years, with emphasis on differential diagnosis. Cancer. 1984; 54(3):535-40. https://doi.org/10.1002/1097-0142(19840801)54:3<535::AID-CNCR2820540325>3.0.CO;2-T

Vasko VV, Gaudart J, Allasia C, Savchenko V, Di Cristofaro J, Saji M, Ringel MD, De Micco C. Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma. European journal of endocrinology. 2004; 151(6):779-86. https://doi.org/10.1530/eje.0.1510779 PMid:15588246

KulaÃ§oÄŸlu S, ErkÄ±lÄ±nÃ§ G. Imp3 expression in benign and malignant thyroid tumours and hyperplastic nodules. Balkan medical journal. 2015; 32(1):30. https://doi.org/10.5152/balkanmedj.2015.15547 PMid:25759769 PMCid:PMC4342135

Scognamiglio T, Hyjek E, Kao J, Chen YT. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. American journal of clinical pathology. 2006; 126(5):700-8. https://doi.org/10.1309/044V86JN2W3CN5YB PMid:17050067

de Matos PS, Ferreira AP, de Oliveira Facuri F, AssumpÃ§Ã£o LV, Metze K, Ward LS. Usefulness of HBMEâ€1, cytokeratin 19 and galectinâ€3 immunostaining in the diagnosis of thyroid malignancy. Histopathology. 2005; 47(4):391-401. https://doi.org/10.1111/j.1365-2559.2005.02221.x PMid:16178894

de Matos LL, Del Giglio AB, Matsubayashi CO, de Lima Farah M, Del Giglio A, da Silva Pinhal MA. Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagnostic pathology. 2012; 7(1):97. https://doi.org/10.1186/1746-1596-7-97 PMid:22888980 PMCid:PMC3523001

Ito Y, Yoshida H, Tomoda C, Miya A, Kobayashi K, Matsuzuka F, Yasuoka H, Kakudo K, Inohara H, Kuma K, Miyauchi A. Galectinâ€3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma. Pathology. 2005; 37(4):296-8. https://doi.org/10.1080/00313020500169545 PMid:16194828

Mehrotra P, Okpokam A, Bouhaidar R, Johnson SJ, Wilson JA, Davies BR, Lennard TW. Galectinâ€3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology. 2004; 45(5):493-500. https://doi.org/10.1111/j.1365-2559.2004.01978.x PMid:15500653

Sahoo S, Hoda SA, Rosai J, DeLellis RA. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. American journal of clinical pathology. 2001; 116(5):696-702. https://doi.org/10.1309/6D9D-7JCM-X4T5-NNJY PMid:11710686

Bahadir B, Behzatoglu K, Bektas S, Bozkurt ER, Ozdamar SO. CD10 expression in urothelial carcinoma of the bladder. Diagnostic pathology. 2009; 4(1):38. https://doi.org/10.1186/1746-1596-4-38 PMid:19917108 PMCid:PMC2780995

Tomoda C, Kushima R, Takeuti E, Mukaisho KI, Hattori T, Kitano H. CD10 expression is useful in the diagnosis of follicular carcinoma and follicular variant of papillary thyroid carcinoma. Thyroid. 2003; 13(3):291-5. https://doi.org/10.1089/105072503321582105 PMid:12729479

Millar EK, Waldron S, Spencer A, Braye S. CD10 positive thyroid marginal zone non-Hodgkin lymphoma. Journal of clinical pathology. 1999; 52(11):849-50. https://doi.org/10.1136/jcp.52.11.849 PMid:10690178 PMCid:PMC501601

Yegen G, Demir MA, Ertan Y, Nalbant OA, TunÃ§yÃ¼rek M. Can CD10 be used as a diagnostic marker in thyroid pathology?. Virchows Archiv. 2009; 454(1):101. https://doi.org/10.1007/s00428-008-0698-2 PMid:19031085

DeLellis RA. Pathology and genetics tumor of endocrine organs. World Health Organization classification of tumors. 2004.

Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, Chan JK, DeLellis RA, Harach HR, Kakudo K, LiVolsi VA. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. The American journal of surgical pathology. 2004; 28(10):1336-40. https://doi.org/10.1097/01.pas.0000135519.34847.f6 PMid:15371949

Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms: frequent expression in renal cell carcinoma and endometrial stromal sarcoma. American journal of clinical pathology. 2000; 113(3):374-82. https://doi.org/10.1309/8VAV-J2FU-8CU9-EK18 PMid:10705818

Shipp MA, Look AT. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! Blood. 1993; 82(4):1052-70. PMid:8102558

Mechtersheimer G, MÃ¶ller P. Expression of the common acute lymphoblastic leukemia antigen (CD10) in mesenchymal tumors. The American journal of pathology. 1989; 134(5):961. PMid:2541615 PMCid:PMC1879890

Mokhtari M, Ameri F. Diagnostic value of CD-10 marker in differentiating of papillary thyroid carcinoma from benign thyroid lesions. Advanced biomedical research. 2014; 3.

Yasuda M, Itoh J, Satoh Y, Kumaki N, Tsukinoki K, Ogane N, Osamura RY. Availability of CD10 as a histopathological diagnostic marker. Acta Histochemica et Cytochemica. 2005; 38(1):17-24. https://doi.org/10.1267/ahc.38.17